Eledon Pharmaceuticals

ELDN · NASDAQ

$2.26+$0.095 (+4.40%)TodayMarket closed · Oct 20, 7:41 PM ET

Prev close $2.16

ELDN analyst rating

BuyConsensus of 2 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy2
Hold0
Underperform0
Sell0

12-month price target · 7 analysts

Average $9.18 (+307.1% upside)

Low: $7.07
Now: $2.26
High: $12.60

Upgrades and downgrades

The latest rating actions, newest first

ELDN analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Rodman & Renshaw	Jul 21, 2026	Initiates	Buy	$12.00	0%
Guggenheim	Nov 18, 2025	Maintains	Buy	$9.00 → $8.00	66%

The case for and against

Updated Feb 9, 2026

Bull case

Eledon Pharmaceuticals Inc. has produced encouraging results regarding its lead compound, tegoprubart, which demonstrates potential to enhance graft survival and kidney function in transplant patients compared to standard care. The favorable safety and tolerability profile observed in the recent Phase 2 BESTOW trial, showing significantly reduced adverse effects compared to tacrolimus, reinforces the compound's therapeutic promise. Furthermore, the company's focus on targeting the CD40L pathway positions it strategically within the lucrative transplantation and autoimmune disease markets, suggesting a strong foundation for future growth and advancements in treatment efficacy.

Bear case

Eledon Pharmaceuticals reported a net loss of $17.5 million for 3Q 2025, a significant decline from the prior year's net income of $77 million, which had been bolstered by a substantial non-cash gain. The decrease in operational expenses, noted at $19.1 million in the latest quarter compared to $20.5 million previously due to reduced R&D spending, may not substantially mitigate the financial challenges ahead. Multiple risks, including the potential failure of the company's lead asset, tegoprubart, in clinical trials, regulatory approvals, and market penetration, coupled with concerns around reimbursement and dilution, present a substantial negative outlook for the stock.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.